UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Participation improves while semiconductors retreat. SPY gained 1.16%, QQQ 0.23% and DIA 0.98%; IWM fell 0.92% and SMH 4.32%. Nine of eleven sector ETFs advanced. Price changes compare October 9 with October 2 in the same daily data series.
Nine positive sector ETFs out of eleven are a broader result than the prior edition. Utilities, energy and staples lead this sample; technology and industrials decline. This is sector participation, not an advance/decline count across individual stocks.
Our interpretation: gains outside technology diversify leadership, but weak small caps and semiconductors prevent an unqualified risk-on reading. The next test is whether inflation releases and earnings guidance support margins without another rise in financing pressure.
XLU +3.97%, XLE +3.60% and XLP +3.60%; IGV +3.91% versus SMH -4.32%. These are fund price changes, not company forecasts.
TLT +0.65%, IEF +0.39%, LQD +0.57% and HYG +0.42%. Fund prices do not establish a specific yield or credit-spread change.
XBI -0.43% and IBB +0.58%. AstraZeneca completed its $2 billion Summit equity investment on October 5; financing and FDA review remain separate.
Watch whether broader sector participation persists and small caps join the advance. Compare cash generation with earnings growth.
September services price pressure, the October 14 CPI, October 15 PPI and energy costs can challenge margins. No policy outcome is assumed.
October 14, 8:30 a.m. ET / 14:30 Europe/Rome. BLS release schedule. The outcome is not yet known.
Daily SIP bars in USD, October 9 versus October 2; Friday versus October 8. Price changes exclude distributions. The live chart may show later data.
| Ticker | Instrument / sector | Week | Oct 9 close | Friday |
|---|---|---|---|---|
| $SMH | Semiconductors | -4.32% | $603.33 | -0.65% |
| $IGV | Software | +3.91% | $112.67 | +2.81% |
| $XLK | Technology | -0.52% | $198.78 | +0.51% |
| $XLE | Energy | +3.60% | $65.08 | -0.25% |
| $XLU | Utilities | +3.97% | $41.41 | +0.83% |
| $QQQ | Nasdaq-100 ETF | +0.23% | $751.27 | +0.49% |
| $IWM | Russell 2000 ETF | -0.92% | $278.94 | +0.49% |
| $SPY | S&P 500 ETF | +1.16% | $778.57 | +0.60% |
| $XLI | Industrials | -0.41% | $169.25 | +0.50% |
| $XBI | Biotech equal-weight | -0.43% | $153.77 | +3.00% |
| $XLY | Consumer discretionary | +2.55% | $112.85 | +1.02% |
| $DIA | Dow ETF | +0.98% | $516.11 | +0.87% |
| $XLRE | Real estate | +1.96% | $41.61 | +1.86% |
| $XLP | Consumer staples | +3.60% | $83.43 | +0.01% |
| $XLB | Materials | +1.17% | $49.43 | +0.32% |
| $IBB | Biotech ETF | +0.58% | $206.49 | +3.00% |
| $XLC | Communication services | +0.05% | $110.38 | -1.51% |
| $XLF | Financials | +2.32% | $54.73 | +0.92% |
| $XLV | Health care | +2.79% | $170.81 | +1.58% |
GLD +1.17%, SLV +0.07%, UNG +5.16% and UUP +0.45%. ETF exposure, fees and futures roll effects can differ from spot returns. Treasury-fund gains do not imply a measured yield change.
| Ticker | Instrument / sector | Week | Oct 9 close | Friday |
|---|---|---|---|---|
| $XOP | Oil & gas exploration ETF | +3.56% | $191.52 | -1.02% |
| $UUP | US dollar fund | +0.45% | $29.02 | +0.14% |
| $EEM | Emerging-market equities | -1.29% | $66.80 | +1.06% |
| $USO | Oil fund | +0.56% | $148.20 | +0.42% |
| $IEF | 7–10 year Treasury ETF | +0.39% | $89.40 | -0.06% |
| $HYG | High-yield corporate ETF | +0.42% | $77.23 | +0.12% |
| $LQD | Investment-grade corporate ETF | +0.57% | $102.41 | -0.06% |
| $EFA | Developed ex-US equities | -0.54% | $103.40 | +0.68% |
| $FXI | China large-cap ETF | +3.16% | $34.24 | +2.36% |
| $TLT | 20+ year Treasury ETF | +0.65% | $77.98 | +0.14% |
| $GLD | Gold ETF | +1.17% | $384.58 | +1.57% |
| $SLV | Silver ETF | +0.07% | $54.78 | +2.49% |
| $UNG | Natural gas fund | +5.16% | $11.01 | +1.85% |
Each daily return uses the preceding session in the same price series. Daily changes compound to the weekly change; adding rounded percentages will not reproduce it exactly.
| Session | SPY | QQQ | IWM | SMH | IGV | Basis |
|---|---|---|---|---|---|---|
| 2026-10-05 | +0.67% | +0.88% | +0.66% | +0.52% | +1.19% | Regular-session close comparison |
| 2026-10-06 | +0.55% | +0.46% | -0.72% | -0.22% | +1.31% | Regular-session close comparison |
| 2026-10-07 | -0.24% | -0.25% | -1.29% | -1.18% | -1.19% | Regular-session close comparison |
| 2026-10-08 | -0.42% | -1.34% | -0.05% | -2.84% | -0.23% | Regular-session close comparison |
| 2026-10-09 | +0.60% | +0.49% | +0.49% | -0.65% | +2.81% | Regular-session close comparison |
September Services PMI was 54.9, down from 55.4, while the Prices Index rose to 74.0 from 72.6. New orders were 59.8 and employment 50.1. These are survey indexes, not inflation rates. ISM
On September 16 the Fed raised its target range by 25 basis points to 3.75–4.00%. This is the last statement checked for this edition; it is not a decision taken during October 5–9. Federal Reserve
BLS schedules September CPI for October 14, PPI for October 15 and import/export prices for October 16, all at 8:30 a.m. ET. The outcomes are not yet known. BLS
Expanding services activity can support revenue while input-cost pressure weighs on profitability. A PMI result does not determine the next Fed decision; margin guidance and financing costs are independent cross-checks.
Delta reported October 9: September-quarter GAAP revenue $20.2 billion, EPS $1.15 and operating margin 7.2%; adjusted revenue $17.6 billion, EPS $1.72 and operating margin 9.4%. Keeping the two bases separate matters. Delta results
PepsiCo reported October 8: revenue $25.274 billion, up 5.6%, organic growth 3.1%, GAAP EPS $2.23 and core EPS $2.34. Core operating margin declined 35 basis points, despite the increase in reported operating margin. SEC earnings release
The next-week risk is the translation of sales into earnings: energy and other input costs can offset demand. Compare GAAP and adjusted measures consistently; neither company is a proxy for the whole market.
XBI -0.43%, IBB +0.58%. Different portfolio weights explain why the funds are not interchangeable sector measures.
AstraZeneca completed a $2 billion investment in convertible preferred stock. The proceeds strengthen funding; they do not establish approval, product revenue or a positive regulatory outcome. AstraZeneca release
Summit’s ivonescimab review remains separate from the financing transaction. The clinical endpoint hierarchy and the FDA assessment must be evaluated on their own evidence.
The next week is October 12–16. All times follow agency schedules. Europe changes clocks October 25, before the US: the October 29 release is therefore at 13:30 in Rome. Dates can be revised.
Alpaca SIP daily bars as of October 10: 32 ETFs, six sessions from October 2 through October 9, 192 observations. All comparisons use the same feed and daily-series basis; price changes exclude distributions and are not total returns or live prices. Alpaca
Primary economic and company releases are linked in each section. Sector breadth is the count of positive returns among eleven sector ETFs, not stock-level breadth. Interpretations are editorial and do not attribute moves to a single cause or to an unconfirmed consensus surprise.
Join the Merlintrader Telegram channel for market recaps, biotech catalyst updates and Stock Hub refreshes as they go live.
Join @merlintraderpub_com on TelegramTrack upcoming PDUFA dates, FDA advisory committees, clinical readouts and regulatory decisions in one place.
Open the Biotech Catalyst Calendar
